The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2015 Release

July 27, 2015EISAI SUBMITS NEW DRUG APPLICATION IN JAPAN FOR IN-HOUSE-DISCOVERED ANTIEPILEPTIC DRUG PERAMPANEL AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES
July 21, 2015JCR AND EISAI CONCLUDE FEASIBILITY STUDY AGREEMENT ON APPLICATION OF BLOOD-BRAIN-BARRIER PENETRATION TECHNOLOGY TO DISCOVER NEW TREATMENTS
July 16, 2015EISAI ENTERS AGREEMENT TO TRANSFER NORTH CAROLINA PLANT IN THE U.S. TO BIOGEN
July 15, 2015LAUNCH OF STACIA CLEIA PIVKA-II EISAI DIAGNOSTIC KIT FOR DETECTING HEPATOCELLULAR CARCINOMA TUMOR MARKER WITH AUTOMATED IMMUNOANALYZER
June 26, 2015 EISAI TO LAUNCH NEW FINE GRANULE FORMULATION OF TACHYARRHYTHMIA TREATMENT TAMBOCOR® SUITABLE FOR PEDIATRIC PATIENTS IN JAPAN
June 25, 2015 EUROPEAN COMMISSION APPROVES INDICATION EXPANSION OF EISAI’S ANTIEPILEPTIC AGENT FYCOMPA® FOR ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
June 22, 2015 U.S. FDA APPROVES EISAI’S ANTIEPILEPTIC AGENT FYCOMPA® AS ADJUNCTIVE TREATMENT FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
June 10, 2015 EISAI LAUNCHES ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) IN UNITED KINGDOM INDICATED FOR ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE
June 1, 2015 PHASE II TRIAL RESULTS ON ANTICANCER AGENT LENVIMA® IN RENAL CELL CARCINOMA TO BE DETAILED IN ORAL PRESENTATION AT 51ST ASCO ANNUAL MEETING
COMBINATION THERAPY WITH EVEROLIMUS DEMONSTRATES SIGNIFICANT EXTENSION IN PROGRESSION-FREE SURVIVAL
June 1, 2015 EISAI RECEIVES EUROPEAN COMMISSION APPROVAL OF ANTICANCER AGENT LENVIMA® FOR TREATMENT OF ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE
May 30, 2015 ANTICANCER AGENT HALAVEN® SHOWS SIGNIFICANT EXTENSION IN OVERALL SURVIVAL IN PHASE III STUDY ON SOFT TISSUE SARCOMA
Phase III data to be presented in a Soft Tissue Sarcoma oral session at ASCO
May 29, 2015 EISAI SUBMITS APPLICATIONS FOR REEVALUATION OF EFFICACY AND PARTIAL CHANGE TO LABEL OF EGG WHITE LYSOZYME PREPARATION NEUZYM® BASED ON RESULTS OF REEVALUATION STUDIES
May 29, 2015 AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA®, a Fully Human Anti-TNF-α Monoclonal Antibody, in the Treatment of Ankylosing Spondylitis
May 27, 2015 EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRA-HIGH DOSE PREPARATION AS TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN
May 27, 2015 EISAI RECEIVES POSITIVE CHMP OPINION ON INDICATION EXPANSION FOR ANTIEPILEPTIC AGENT FYCOMPA® (PERAMPANEL) AS ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
May 21, 2015 EISAI TO PROMOTE CLINICAL TRIAL DATA DISCLOSURE FOR THE ADVANCEMENT OF SCIENCE AND MEDICINE
May 20, 2015 EISAI LAUNCHES IN-HOUSE DEVELOPED NOVEL ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) AS TREATMENT FOR UNRESECTABLE THYROID CANCER IN JAPAN
May 14, 2015 Notification Regarding Partial Amendment to the Articles of Incorporation
May 14, 2015 EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 51ST ASCO ANNUAL MEETING
HIGHLIGHTS INCLUDE NEW CLINICAL DATA ON HALAVEN® (ERIBULIN) IN SOFT TISSUE SARCOMA AND ON LENVIMA® (LENVATINIB) IN RENAL CELL CARCINOMA
April 27, 2015 EISAI AND NIHON MEDI-PHYSICS ENTER COLLABORATION AGREEMENT TO CONTRIBUTE TO DIAGNOSIS AND TREATMENT OF DEMENTIA WITH LEWY BODIES
April 24, 2015 EISAI COMMENCES BUSINESS IN MEXICO, AIMS TO EXPAND CONTRIBUTION TO PATIENTS IN LATIN AMERICA
ANTICANCER AGENTS HALAVEN® AND GLIADEL® NEWLY LAUNCHED
April 13, 2015 EISAI AND GENOMICS PLC TO COLLABORATE IN ANALYSES OF LARGE-SCALE GENOTYPE/PHENOTYPE DATA TO INFORM DRUG DEVELOPMENT
April 3, 2015 NIIGATA UNIVERSITY AND EISAI PRESENT RESULTS OF JOINT RESEARCH IN U.S. ACADEMIC JOURNAL
MEASURING COGNITIVE DECLINE IN PATIENTS WITH ALZHEIMER'S DISEASE USING BLOOD-BASED BIOMARKERS
March 30, 2015 EISAI RECEIVES POSITIVE OPINION FROM EMA'S CHMP ON ANTICANCER AGENT LENVIMA® FOR TREATMENT OF ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE
CHMP Opinion Based on Positive SELECT Study Data
March 26, 2015 EISAI RECEIVES APPROVAL IN JAPAN FOR ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) AS TREATMENT FOR UNRESECTABLE THYROID CANCER
March 12, 2015 STATEMENT REGARDING CHANGES TO STRATEGIC PARTNERSHIP WITH EPIZYME, INC. TO DISCOVER, DEVELOP AND COMMERCIALIZE ANTICANCER THERAPIES TARGETING EZH2 EPIGENETIC ENZYME
March 5, 2015 Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored
March 3, 2015 CHINA JSFDA ACCEPTS EISAI'S APPLICATION SEEKING ADDITIONAL INDICATION OF SEVERE ALZHEIMER'S DISEASE FOR ARICEPT®
March 2, 2015 EISAI LAUNCHES ANTICANCER AGENT LENVIMA™ IN THE UNITED STATES
FIRST COUNTRY IN THE WORLD TO GAIN ACCESS TO NEW TREATMENT OPTION
February 25, 2015 EISAI TO ESTABLISH ORAL SOLID DOSE PRODUCTION FACILITY AT NEW SUZHOU PLANT IN CHINA
February 25, 2015 PHASE III TRIAL OF ANTICANCER AGENT HALAVEN® IN SOFT TISSUE SARCOMA SHOWS OVERALL SURVIVAL BENEFIT IN PRIMARY ENDPOINT
February 24, 2015 ADDITIONAL EXPLORATORY ANALYSIS OF PHASE II TRIAL SUGGESTS ANTICANCER AGENT LENVATINIB EXTENDS OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
February 24, 2015 EISAI LAUNCHES PROTON PUMP INHIBITOR PARIET® TABLETS 5 MG IN JAPAN
February 19, 2015 EISAI RECEIVES APPROVAL IN JAPAN FOR FINE GRANULE FORMULATION OF ANTI-ARRHYTHMIC AGENT TAMBOCOR® SUITABLE FOR PEDIATRIC PATIENTS
February 16, 2015 U.S. FDA APPROVES ANTICANCER AGENT LENVIMA™ (LENVATINIB MESYLATE) AS TREATMENT FOR RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
February 16, 2015 EISAI RECEIVES APPROVAL OF ANTIEPILEPTIC DRUG BANZEL® (RUFINAMIDE) AS ADJUNCTIVE TREATMENT FOR PEDIATRIC PATIENTS IN THE UNITED STATES
U.S. PATENT EXCLUSIVITY EXTENDED BY SIX MONTHS
February 12, 2015 ANTICANCER AGENT LENVATINIB PHASE III TRIAL RESULTS PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE
SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL SHOWN IN PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
February 5, 2015 NOTICE REGARDING EISAI'S OPTIONS RELATING TO BIOGEN IDEC'S INVESTIGATIONAL ANTI-ALZHEIMER'S DISEASE TREATMENTS
January 30, 2015 PHASE II TRIAL OF ANTICANCER AGENT LENVATINIB IN RENAL CELL CARCINOMA MEETS PRIMARY ENDPOINT
January 30, 2015 Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2015
January 26, 2015 EISAI AND AJINOMOTO PHARMACEUTICALS LAUNCH BRANCHED-CHAIN AMINO ACID FORMULA LIVAMIN® ORAL GRANULES IN THE PHILIPPINES
January 23, 2015 EISAI LISTED IN GLOBAL 100 SUSTAINABILITY INDEX FOR THIRD CONSECUTIVE YEAR
ONLY COMPANY FROM JAPAN INCLUDED IN 2015
January 5, 2015 PHASE III TRIAL OF ANTIEPILEPTIC DRUG PERAMPANEL AS ADJUNCTIVE THERAPY IN PATIENTS WITH REFRACTORY PARTIAL-ONSET SEIZURES CONDUCTED IN ASIA INCLUDING JAPAN AND CHINA MEETS PRIMARY ENDPOINT

Back to Top

2014 Release

December 26, 2014 EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF PROTON PUMP INHIBITOR PARIET® FOR USE IN PREVENTION OF RECURRENT GASTRIC OR DUODENAL ULCER CAUSED BY LOW-DOSE ASPIRIN THERAPY AND ADDITIONAL 5 MG TABLET FORMULATION IN JAPAN
December 17, 2014 EISAI LISTED FOR 13TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
December 10, 2014 EISAI DEMONSTRATES EFFICACY OF INVESTIGATIONAL DUAL OREXIN RECEPTOR ANTAGONIST E2006 IN SLEEP INITIATION AND MAINTENANCE
DATA FROM PHASE II CLINICAL TRIAL FOR INSOMNIA PRESENTED AT 53RD AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING
December 8, 2014 EISAI PRESENTS RESULTS FROM PHASE III TRIAL OF ANTIEPILEPTIC DRUG FYCOMPA® AS ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AT 68TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
December 2, 2014 EISAI TO PRESENT NEW RESEARCH ON HALAVEN® (ERIBULIN) AT 37TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
December 1, 2014 EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR ANTICANCER AGENT LENVATINIB IN SOUTH KOREA
December 1, 2014 EISAI ESTABLISHES HOLDING COMPANY EISAI CHINA HOLDINGS LTD. IN CHINA
November 28, 2014 EISAI OPENS NEW PARENTERAL FACILITY IN CHINA
November 27, 2014 EISAI OPENS NEW PACKAGING FACILITY AT HATFIELD PRODUCTION PLANT IN U.K.
November 25, 2014 EISAI ANNOUNCES LAUNCH OF ANTICANCER AGENT HALAVEN® AS COMPANY'S FIRST PRODUCT IN BRAZIL
LAUNCH MARKS THE COMMENCEMENT OF BUSINESS IN LATIN AMERICA
November 21, 2014 EISAI LAUNCHES ANTIEPILEPTIC DRUG FYCOMPA® IN HONG KONG
FIRST REGION IN ASIA TO GAIN ACCESS TO NEW FIRST-IN-CLASS THERAPY
November 17, 2014 EISAI'S RANKING SIGNIFICANTLY INCREASES IN THE ACCESS TO MEDICINE INDEX 2014
November 7, 2014 STATEMENT REGARDING THE GERMAN FEDERAL JOINT COMMITTEE'S DECISION ON ANTIEPILEPTIC DRUG FYCOMPA®
November 4, 2014 LORCASERIN MEETS PRIMARY ENDPOINT AND CONFIRMS PROOF-OF-CONCEPT AS POTENTIAL AID FOR SMOKING CESSATION IN INVESTIGATIONAL PHASE II CLINICAL STUDY
October 29, 2014 EISAI ANNOUNCES TOP-LINE RESULTS OF INVESTIGATIONAL STUDY ON COADMINISTRATION OF LORCASERIN AND PHENTERMINE
Trial Supports Safety and Tolerability After 12 Weeks of Treatment
October 23, 2014 EISAI SUPPORTS CYCLONE RELIEF EFFORTS IN ANDHRA PRADESH, INDIA
October 21, 2014 U.S. FDA ACCEPTS sNDA FOR ANTIEPILEPTIC AGENT FYCOMPA® AS ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
October 15, 2014 U.S. FDA ACCEPTS EISAI'S sNDA FOR BANZEL® (RUFINAMIDE) AS ADJUNCTIVE TREATMENT IN PEDIATRIC PATIENTS WITH LENNOX-GASTAUT SYNDROME
October 15, 2014 U.S. FDA GRANTS PRIORITY REVIEW STATUS TO NDA FOR ANTICANCER AGENT LENVATINIB
October 14, 2014 U.S. FDA APPROVES ANTIEMETIC AGENT AKYNZEO® FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)
World’s First Oral Fixed Combination Targeting Two Critical Pathways Involved in CINV
October 1, 2014 EISAI LAUNCHES ANTICANCER AGENT HALAVEN® IN AUSTRALIA
FIRST EXCLUSIVELY MARKETED PRODUCT TO MARK COMMENCEMENT OF FULL-SCALE OPERATIONS
September 30, 2014 PHASE III TRIAL OF ARICEPT® IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE IN CHINA MEETS PRIMARY ENDPOINT
September 26, 2014 EISAI SUBMITS APPLICATION IN JAPAN FOR INDICATION EXPANSION OF VASCULAR EMBOLIZATION DEVICE DC BEAD® TO INCLUDE TREATMENT OF HYPERVASCULARIZED TUMORS AND ARTERIOVENOUS MALFORMATIONS
September 19, 2014 ARICEPT® APPROVED IN JAPAN AS TREATMENT FOR DEMENTIA WITH LEWY BODIES
WORLD'S FIRST TREATMENT FOR BOTH ALZHEIMER'S DISEASE AND DEMENTIA WITH LEWY BODIES
September 18, 2014 EISAI SELECTED SUCCESSIVELY FOR MEMBERSHIP OF DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2014
September 17, 2014 EISAI TO PRESENT LATEST CLINICAL DATA ON HALAVEN® (ERIBULIN) AND LENVATINIB AT 39TH ESMO CONGRESS
September 16, 2014 EISAI ENTERS TWO JOINT RESEARCH AGREEMENTS TO DEVELOP NEW ANTIMALARIAL MEDICINES
IN COLLABORATION WITH ST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEDICINES FOR MALARIA VENTURE AND BROAD INSTITUTE
September 10, 2014 EISAI AND KYORIN ENTER INTO AGREEMENT CONCERNING COMPOUND LIBRARY USE FOR THE DEVELOPMENT OF NEW ANTIBACTERIAL AGENTS
September 3, 2014 EISAI'S U.S. SUBSIDIARY EISAI INC. TO DIVEST U.S. RIGHTS FOR ZONEGRAN® TO CONCORDIA PHARMACEUTICALS INC.
August 28, 2014 EISAI INTRODUCES NEW LIFESTYLE INFORMATION WEBSITE “BreCare Garden” FOR PATIENTS WITH BREAST CANCER
INCLUDES INFORMATION ON PATIENT FRIENDLY SPA RESORTS,
BEAUTY SALONS AND FASHION ITEMS AVAILABLE IN JAPAN
August 20, 2014 EISAI SUBMITS APPLICATIONS FOR ANTIEPILEPSY AGENT FYCOMPA® SIMULTANEOUSLY IN EUROPE AND U.S. SEEKING INDICATION EXPANSION AS ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
August 18, 2014 EISAI AND ZERIA CONCLUDE LICENSE AGREEMENT CONCERNING A NEW PROTON PUMP INHIBITOR IN JAPAN
August 18, 2014 EISAI SUBMITS MARKETING APPROVAL APPLICATIONS FOR ANTICANCER AGENT LENVATINIB SIMULTANEOUSLY IN EUROPE AND U.S.
August 8, 2014 EISAI ANNOUNCES TOP-LINE PHASE III TRIAL RESULTS OF ERIBULIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING AT LEAST TWO PRIOR REGIMENS
August 7, 2014 EISAI SUPPORTS EARTHQUAKE RELIEF EFFORTS IN YUNNAN, CHINA
August 1, 2014 EISAI ANNOUNCES PERSONNEL CHANGES FOR ITS CHINESE SUBSIDIARY EISAI CHINA INC. EFFECTIVE AUGUST 1, 2014
August 1, 2014 CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
July 31, 2014 EMA ACCEPTS EISAI'S REQUEST FOR ACCELERATED ASSESSMENT OF ANTICANCER AGENT LENVATINIB
LEADING TOWARD SUBMISSION FOR APPROVAL IN EUROPE
July 3, 2014 EISAI RECEIVES EUROPEAN COMMISSION APPROVAL OF INDICATION EXPANSION FOR ANTICANCER AGENT HALAVEN® FOR ADVANCED BREAST CANCER AFTER ONLY ONE PRIOR CHEMOTHERAPY
July 2, 2014 EISAI TO LAUNCH FIRST CHOCOLA BB BRAND PRODUCT “CHOCOLA BB® ROYAL DRINK” IN CHINA
June 26, 2014 EISAI SUBMITS FIRST MARKETING AUTHORIZATION APPLICATION FOR ANTICANCER AGENT LENVATINIB IN JAPAN
June 25, 2014 LAUNCH OF TYPE IV COLLAGEN MEASUREMENT REAGENT KIT “PANASSAY® IV-C [LATEX]” IN JAPAN
June 17, 2014 PHASE III TRIAL OF ANTIEPILEPTIC DRUG FYCOMPA® (PERAMPANEL) MEETS PRIMARY ENDPOINTS AS ADJUNCTIVE THERAPY IN PATIENTS WITH UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
June 2, 2014 EISAI PRESENTS DATA ON HALAVEN® FROM POOLED ANALYSIS OF OVER 1,800 ADVANCED BREAST CANCER PATIENTS AT 50TH ASCO ANNUAL MEETING
SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL FOUND IN HER2 NEGATIVE AND TRIPLE NEGATIVE BREAST CANCER PATIENTS
May 31, 2014 LENVATINIB PHASE III RESULTS SHOW SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
Phase III data for lenvatinib to be presented in a Head and Neck Cancer oral session at ASCO
May 30, 2014 EISAI HONORED WITH PRESTIGIOUS ‘UCL ENTERPRISE PARTNER OF THE YEAR 2014’ AWARD BY UNIVERSITY COLLEGE LONDON (UCL)
For Outstanding Contribution to Neuroscience Research and Entrepreneurship
May 29, 2014 ANTIEMETIC AGENT ALOXI® APPROVED FOR CHILDREN BY THE U.S. FDA
U.S. MARKET EXCLUSIVITY EXTENDED BY SIX MONTHS TO OCTOBER 13, 2015
May 27, 2014 EISAI TO LAUNCH CHOCOLA BB® SPARKLING SALTY NATSUMIKAN FLAVOR
CONTAINS 5 INGREDIENTS THAT HELP BRING OUT THE BEAUTY FROM WITHIN & SODIUM SUPPLEMENT
May 27, 2014 EISAI RECEIVES POSITIVE OPINION FROM EMA'S CHMP ON EXPANDING INDICATION OF ANTICANCER AGENT HALAVEN® FOR USE IN EARLIER-LINE TREATMENT OF ADVANCED BREAST CANCER
May 26, 2014 KAN RESEARCH INSTITUTE COMMENCES FULL-SCALE OPERATION AT NEW FACILITY
AIMS TO DISCOVER AND DEVELOP NEW BIOLOGIC THERAPIES IN KANSAI INTERNATIONAL STRATEGIC INNOVATION ZONE
May 15, 2014 EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 50TH ASCO ANNUAL MEETING
HIGHLIGHTS INCLUDE NEW PHASE III CLINICAL DATA ON INVESTIGATIONAL ANTICANCER AGENT LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
May 12, 2014 EISAI RESUBMITS ANTIEPILEPTIC DRUG FYCOMPA® TO GERMAN FEDERAL JOINT COMMITTEE FOR ADDITIONAL BENEFIT ASSESSMENT
May 9, 2014 EISAI EXPANDS COLLABORATION WITH BIOGEN IDEC TO DEVELOP AND COMMERCIALIZE NEXT GENERATION ALZHEIMER'S DISEASE TREATMENTS TO INCLUDE JAPAN
May 7, 2014 EISAI AND UNIVERSITY OF TSUKUBA INITIATE JOINT INDUSTRY-ACADEMIA DEVELOPMENT OF NOVEL INFLAMMATORY BOWEL DISEASE TREATMENT USING NEW BIOMARKERS
April 24, 2014 “EISAI ACCESS TO MEDICINES (ATM) NAVIGATOR”
EISAI LAUNCHES NEW COMPREHENSIVE INFORMATION WEBSITE ABOUT NEGLECTED TROPICAL DISEASES AND ELIMINATION INITIATIVES
April 15, 2014 EISAI CEO HARUO NAITO APPOINTED KNIGHT COMMANDER OF BRITISH EMPIRE
April 7, 2014 EISAI LAUNCHES NEW ENERGY DRINK “JOMA®”
“CAST A SPELL OF HAPPINESS”
March 31, 2014 U.S. SUBSIDIARY EISAI INC. ASSIGNS WORLDWIDE RIGHTS FOR DNA METHYLATION INHIBITOR DACOGEN® TO OTSUKA
March 28, 2014 Notice Concerning Shelf Registration for Issuance of Stock Options
March 25, 2014 Notice Concerning Voluntary Adoption of International Financial Reporting Standards (IFRS)
March 20, 2014 EISAI ENTERS COLLABORATION WITH LIVERPOOL SCHOOL OF TROPICAL MEDICINE AND UNIVERSITY OF LIVERPOOL TO DISCOVER NOVEL ANTI-WOLBACHIA TARGETED ANTI-FILARIAL DRUGS
JOINT RESEARCH PROJECT AWARDED GHIT FUND GRANT
March 5, 2014 EISAI AND BIOGEN IDEC ENTER COLLABORATION TO DEVELOP AND COMMERCIALIZE ALZHEIMER'S DISEASE TREATMENTS
-Agreement to Enhance R&D Capabilities and Pipeline Aimed at Creating New Therapies to Suppress Alzheimer's Disease Progression-
February 13, 2014 EISAI ANNOUNCES LAUNCH OF PARIET® TRIPLE FORMULATION COMBINATION PACKS RABECURE® 400 AND 800 AND RABEFINE®, FOR PRIMARY AND SECONDARY H. PYLORI ERADICATION RESPECTIVELY, IN JAPAN
February 3, 2014 PHASE III TRIAL SHOWS LENVATINIB MEETS PRIMARY ENDPOINT OF PROGRESSION FREE SURVIVAL BENEFIT IN TREATMENT OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
February 3, 2014 EISAI ANNOUNCES LAUNCH OF VASCULAR EMBOLIZATION DEVICE DC BEAD® IN JAPAN
February 3, 2014 Notification Regarding Results of Voluntary Retirement Program
January 27, 2014 EISAI LISTED IN GLOBAL 100 SUSTAINABILITY INDEX FOR SECOND CONSECUTIVE YEAR
January 22, 2014 EISAI ANNOUNCES LAUNCH OF NEW “CRYSTAL VEIL® MASK BOKIN 24 MINT” FACE MASK SPRAY CONTAINING LONG-ACTING ANTIMICROBIAL AGENT ETAK®
24-HOUR PROTECTION FROM POLLEN, VIRUSES & BACTERIA ADHERING TO FACE MASKS
January 6, 2014 EISAI ANNOUNCES LAUNCH OF ANTIEPILEPTIC DRUG FYCOMPA™ IN U.S.

Back to Top